亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

成都鈉鈳鋰生物科技有限公司  

自制標準品對照品,各類植物提取物

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:李曼
  • 電話:028-61983833
  • 郵件:cdnakeli@163.com
  • 微信:18000507060
  • QQ:1373789011
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 重樓皂苷VII CAS:68124-04-9
重樓皂苷VII CAS:68124-04-9
單價 面議對比
詢價 暫無
發貨 四川成都市付款后3天內
品牌 鈉鈳鋰
過期 長期有效
更新 2021-11-25 12:22
 
詳細信息

nkl-00126
中文名稱:重樓皂苷VII
中文別名:重樓皂甙VII
英文名稱:Polyphyllin VII
英文別名: (3β,25R)-17-Hydroxyspirost-5-en-3-yl O-6-deoxy-α-L-mannopyranosyl-(1→2)-O-[O-6-deoxy-α-L-mannopyranosyl-(1→4)-6-deoxy-α-L-mannopyranosyl-(1→4)]-β-D-glucopyranoside;  Spirostan, β-D-glucopyranoside deriv.; (25R)-17α-Hydroxyspirost-5-en-3β-yl O-α-L-rhamnopyranosyl-(1→2)-O-[O-α-L-rhamnopyranosyl-(1→4)-α-L?rhamnopyranosyl-(1→4)-β-D-glucopyranoside; 17-Hydroxyparis II; Spiro[8H-naphth[2′,1′:4,5]indeno[2,1-b]furan-8,2′-[2H]pyran], β-D-glucopyranoside deriv.;Chonglouoside VII; Dioscinin; Paris VII; Paris saponin VII; Pennogenin 3-O-rhamnosylchacotrioside;  Saponin Tg;Pennogenin 3-O-α-L-rhamnopyranosyl-(1→2)-[α-L-rhamnopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→4)]-β-D-glucopyranoside; Pennogenin 3-O-α-L-rhamnopyranosyl-(1→4)-α-L-rhamnopyranosyl-(1→4)-[α-L-rhamnopyranosyl-(1→2)]-β-D-glucopyranoside;Pennogenin-3-O-α-L-rhamnopyranosyl-(1→4)-O-α-L-rhamnopyranosyl-(1→4)-O-[α-L-rhamnopyranosyl-(1→2)]-O-β-D-glucopyranoside
CAS號:68124-04-9
純度: HPLC≥98%

分子式:C51 H82 O21
分子量:1031.18
外觀:白色結晶粉末
熔點:243-245 °C (de*p)
密度: 1.45±0.1 g/cm3 | Condition: Temp: 20 °C
pKa 值: 12+-.0.70 | Condition: Most Acidic Temp: 25 °C
規格: 20mg 50mg 100mg 500mg g級等應客戶需求包裝.
提取來源:重樓
藥理藥效:有止血、祛痰和抑菌、鎮靜鎮痛、抗早孕殺滅精子、抗細胞毒等作用, 臨床用于治療功能性子宮出血、神經性皮炎、外科炎癥以及腫瘤等, 都有顯著的療效。
儲存條件: 2-8°C,避光、干燥、密封

用途: 用于鑒別、含量測定、藥理實驗、活性篩選等科研、實驗室使用;不得用于注射、食用或其他

供應商:成都鈉鈳鋰生物科技有限公司

©2025 成都鈉鈳鋰生物科技有限公司 版權所有   技術支持:化工網   訪問量:21308  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |